← Back to feed

Immupharma

IMM · AIM · Health Care · mcap £21m today

All announcements

All RNS · 30 Key events · 22

15 Sep 26

New peer-reviewed publication

New peer-reviewed publication reports P140 activity in a preclinical MASH model
RNS 9771803 ↗
15 Sep 26

P140 International Patent Filing Update

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that it has filed an international Patent Cooperation Treaty ("PCT") application relating to its P140 precision medicine approach in autoimmune...
RNS 9771747 ↗
15 Sep 26

Half-year Results

ImmuPharma PLC (LSE:IMM), ("ImmuPharma", the Group or the "Company"), the specialist drug discovery and development company, is pleased to announce its unaudited interim results for the six months ended 30 June 2026 (the "Period").
RNS 9771547 ↗
10 Aug 26

Bioanalytical CRO partner for Kapiglucagon

ImmuPharma selects Kymos Group as bioanalytical CRO partner for Kapiglucagon
RNS 9711926 ↗
22 Jul 26

Thermo Fisher CDMO selected for Kapiglucagon pro

ImmuPharma selects Thermo Fisher Scientific drug product CDMO for Kapiglucagon program
RNS 9680713 ↗
25 Jun 26

2026 Result Of Annual General Meeting

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today.
RNS 9637309 ↗
25 Jun 26

ImmuPharma appoints Bachem for Kapiglucagon API

ImmuPharma appoints Bachem as API manufacturing partner for Kapiglucagon
RNS 9635563 ↗
24 Jun 26

University of Murcia research relating to P140

ImmuPharma plc (LSE AIM: IMM), the specialist drug discovery and development company, notes the recent article published in the scientific journal Autophagy, which reports early-stage research conducted by the University of Murcia ("UoM") relating to the...
RNS 9633221 ↗
04 Jun 26

Incanthera plc – Corporate Update & Board Changes

Incanthera plc - Corporate Update & Board Changes
RNS 9601468 ↗
27 May 26

Final Results Voting rights down

for the twelve months ended 31 December 2025
RNS 9586435 ↗
05 May 26

IMM initiatesIND-Enabling Program for Kapiglucagon

ImmuPharma Initiates IND-Enabling Program for Kapiglucagon to treat Diabetes
RNS 9551006 ↗
09 Apr 26

Chairman’s Open Letter to Shareholders

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, outlines below an open letter to shareholders from the Chairman, Tim McCarthy.
RNS 9511388 ↗
27 Mar 26

P140 Program Update

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to provide an update on its auto-immune technology platform program, P140.
RNS 9494798 ↗
23 Mar 26

Result of WRAP Retail Offer and TVR

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, further to its Fundraising announcement published on 17 March 2026 at 7:00 a.m.
RNS 9485641 ↗
18 Mar 26

‘Investor Meet Company’ presentation on 20 March

ImmuPharma to present live on 'Investor Meet Company' platform
RNS 9479295 ↗
17 Mar 26

WRAP Retail Offer for up to £1.5 million

WRAP Retail Offer for up to £1.5 million
RNS 9477117 ↗
17 Mar 26

P140 Update; Fundraise, Related Party Transaction

IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF THE MATTERS CONTAINED IN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF SUCH INSIDE INFORMATION AS PERMITTED BY UK MAR.
RNS 9476970 ↗
06 Jan 26

Attending JPMorgan Conference & Biotech Showcase

IMMUPHARMA AT JP MORGAN CONFERENCE & BIOTECH SHOWCASE™
RNS 9334990 ↗
24 Nov 25

Corporate Update

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces an update on P140 partnership discussions.
RNS 9251855 ↗
27 Oct 25

Immupharma Attending Bio-europe

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO, Dr Tim Franklin, COO, and Dr Sebastien Goudreau, CSO will be attending the forthcoming Bio-Europe Conference in Vienna, from 3-5 November 2025.
RNS 9195106 ↗
23 Oct 25

Launch of Website; Corporate Update

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the launch of its new corporate website, marking another step in the Company's scientific and corporate evolution and placing its proprietary P140...
RNS 9188383 ↗
13 Oct 25

Appointment of Independent Non-Executive Director

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce the appointment of Ketan Patel to the Board, as an independent Non-Executive Director.
RNS 9166015 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.